{"name":"Biocon Biologics UK PLC","slug":"biocon-biologics-uk-plc","ticker":"","exchange":"","domain":"bioconbiologicsuk.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Bmab1200","genericName":"Bmab1200","slug":"bmab1200","indication":"Other","status":"phase_3"},{"name":"Bmab 1000","genericName":"Bmab 1000","slug":"bmab-1000","indication":"Other","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Stelara","genericName":"Stelara","slug":"stelara","indication":"Crohn's disease","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Herceptin Hylecta®","genericName":"Herceptin Hylecta®","slug":"herceptin-hylecta","indication":"HER2-positive early breast cancer (adjuvant and neoadjuvant treatment)","status":"marketed"}]}],"pipeline":[{"name":"Stelara","genericName":"Stelara","slug":"stelara","phase":"marketed","mechanism":"Stelara binds to the p40 subunit of IL-12 and IL-23, reducing inflammation in autoimmune diseases.","indications":["Crohn's disease","Plaque psoriasis","Psoriasis","Psoriasis with arthropathy","Ulcerative colitis"],"catalyst":""},{"name":"Bmab1200","genericName":"Bmab1200","slug":"bmab1200","phase":"phase_3","mechanism":"Bmab1200 is a monoclonal antibody targeting a specific immune or disease-related antigen to modulate immune response or block pathogenic signaling.","indications":[],"catalyst":""},{"name":"Bmab 1000","genericName":"Bmab 1000","slug":"bmab-1000","phase":"phase_3","mechanism":"Bmab 1000 is a monoclonal antibody targeting a specific molecular pathway, though the exact target is not publicly disclosed in available sources.","indications":[],"catalyst":""},{"name":"Herceptin Hylecta®","genericName":"Herceptin Hylecta®","slug":"herceptin-hylecta","phase":"marketed","mechanism":"Herceptin Hylecta is a subcutaneous formulation of trastuzumab that binds to HER2 receptors on cancer cells to block growth signaling and trigger immune-mediated cell death.","indications":["HER2-positive early breast cancer (adjuvant and neoadjuvant treatment)","HER2-positive metastatic breast cancer","HER2-positive gastric or gastroesophageal junction adenocarcinoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTFAxTXNtR1lrU3JXcGFSM2ZrNzlPaXVZWjhJdHhCNXQtSzFJZHl0SW5iaWo1bllSbmVTVFRvdVVTakg3T3FNMlFRRm91YzBaMUtNdFJYOTJmOUVhaUxVV3VqbXg5N2hNOGpadm9TM3UtMmZBRUhlVlhuR01Oc1ZoQQ?oc=5","date":"2025-10-17","type":"pipeline","source":"Fortune Business Insights","summary":"U.K. Pharmaceuticals Market Size, Share | Growth Report [2032] - Fortune Business Insights","headline":"U.K. Pharmaceuticals Market Size, Share | Growth Report [2032]","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxPNVVhWVVuNXpsTXhXWTlORV9mZmFiT0tQd2N5amJjQ3JreG1DVHcyelpLbVJFVEstaVR5UTF1eWxxemFJRDUwWW4yYV9BaXpDYjVkSkN0QkM1OUM0cFRQSVA5X2NFTVNlMzJxX3lhWmN6R1d0S1kxZnY3SXJIWTd6UnU5dHdSOGxHMVE?oc=5","date":"2024-08-29","type":"pipeline","source":"Pharmaceutical Technology","summary":"Biocon Biologics signs agreement with Janssen to market Bmab 1200 - Pharmaceutical Technology","headline":"Biocon Biologics signs agreement with Janssen to market Bmab 1200","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxOUDZwbDJ1WTBWOU02Y1RSeGNwSjBQZjBISWxKU2h3UEY1V08xMmtBbU1qN0piczNOSWs2dVd4YTFXbnVJNEV6cFFZTDNfZ1BJR3A2WXF1c21JVGtzbjVGZTl2TmVmbl91LXIwZnl5T2JMTW0wTlRLQzl2eTBBYkNnM0VXRUpHT18zMXB2MHU5VTB6Zw?oc=5","date":"2023-09-04","type":"patent","source":"Pharmaceutical Technology","summary":"Biocon Generics purchases Eywa’s manufacturing facility in US - Pharmaceutical Technology","headline":"Biocon Generics purchases Eywa’s manufacturing facility in US","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2023-06-22","type":"pipeline","source":"PR Newswire","summary":"Osteoporosis Market to Accelerate Substantially, Assesses DelveInsight | Key Companies to Look Out For - Teva, Novartis, Amgen, USB, Jiangsu HengRui Medicine, Shanghai JMT-Bio, Eli Lilly and Company, ","headline":"Osteoporosis Market to Accelerate Substantially, Assesses DelveInsight | Key Companies to Look Out For - Teva, Novartis,","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTE5FbUd0SHUzc3M5dUo2RTA0ai1ScGRUaHZRSWNIWWM4NURrUVFZQzkxUXVtR2toX09TbDRqNG5JLUVmUnJWMC1Oa0ZZaUVRbC11aG9yc3pxZUE?oc=5","date":"2022-11-14","type":"earnings","source":"Biocon","summary":"Biocon Q2FY23 Revenue at Rs 2,384 Cr, Up 23%; Core EBITDA at Rs 816 Cr, Up 34% Gross R&D Spend at Rs 252 Crore, Up 52% - Biocon","headline":"Biocon Q2FY23 Revenue at Rs 2,384 Cr, Up 23%; Core EBITDA at Rs 816 Cr, Up 34% Gross R&D Spend at Rs 252 Crore, Up 52%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNb3lLOXZBdDJPQnNVYkVFSURtbWhsSnRodGQtNmJ1eWlkOGhzQWxQYm8zZ3ZEWHZRU3AtbWlNTFp3VFBZb2JQak9yM1ZDeWtRbjRzM0gwT1Jtb2cxSUs3V19UN0hhY2ZCV0ZZM09qcGNybDAxdThMRW9scDZwcWlfVjBhYmpNTlBZWWI0WmM4dm0zYWNocUFPV3hFWVLSAaoBQVVfeXFMUGNkV3FualVqV3ZSOHJUWWE5a3Z0N19WOE0wUllzRTZMZ09oZHVxa04yWUVZU2VqcHZWdWZBeFVfVzRKVWVlZmtBU2w5TjNuYmNfZk5RdlR0cXlDR1MydF90SXVlTWN6TUhyN0VYMklSZGIybGpvakRlekFOTVdCc3ZPSEdoSHl6SmdCeFRfTlk3Y0I0YU5DUWVXNFBTNDlXNHBwaXR2UDIycUE?oc=5","date":"2022-02-10","type":"pipeline","source":"Fortune India","summary":"Vaccines, Biologics: Indian Pharma’s New Temptations - Fortune India","headline":"Vaccines, Biologics: Indian Pharma’s New Temptations","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZEFVX3lxTE14VUM1MzZGWTE3VExyRXh1ZmZkN0thWnFvd3JzV00wN3pONFFFMVpiSUI2MF8wVWI1VjYwVHc5bWhvMDExbkE3ZlJTZFRoZ1JXNEVRVWpycWstbmN3QllYVmNKeFY?oc=5","date":"2016-11-26","type":"pipeline","source":"IBEF","summary":"Indian Investment Abroad - Overseas Direct Investment by Indian Companies - IBEF","headline":"Indian Investment Abroad - Overseas Direct Investment by Indian Companies","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"marketed":2,"phase_3":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}